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Background: The Oxford classification of IgA nephropathy (IgAN) provides a useful tool for prediction of renal
prognosis. However, the application of this classification in children with IgAN needs validation in different patient
populations.
Methods: A total of 218 children with IgAN from 7 renal centers in China were enrolled. The inclusion criteria was
similar to the original Oxford study.
Results: There were 98 patients (45%) with mesangial proliferation (M1), 51 patients (23%) with endocapillary
proliferation (E1), 136 patients (62%) with segmental sclerosis/adhesion lesion (S1), 13 patients (6%) with moderate
tubulointerstitial fibrosis (T1 26-50% of cortex scarred), and only 2 patients (1%) with severe tubulointerstitial fibrosis
(T2, >50% of cortex scarred). During a median follow-up duration of 56 months, 24 children (12.4%) developed
ESRD or 50% decline in renal function. In univariate COX analysis, we found that tubular atrophy/interstitial fibrosis
(HR 4.3, 95%CI 1.8-10.5, P < 0.001) and segmental glomerulosclerosis (HR 9.2 1.2-68.6, P = 0.03) were significant
predictors of renal outcome. However, mesangial hypercellularity, endocapillary proliferation, crescents, and necrosis
were not associated with renal prognosis. In the multivariate COX regression model, none of these pathologic
lesions were shown to be independent risk factors of unfavorable renal outcome except for tubular atrophy/
interstitial fibrosis (HR 2.9, 95%CI 1.0-7.9 P = 0.04).
Conclusions: We confirmed tubular atrophy/interstitial fibrosis was the only feature independently associated with
renal outcomes in Chinese children with IgAN.
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IgA nephropathy (IgAN) is the most common primary
glomerulonephritis worldwide. Patients with IgAN have
variable clinical courses, and the decision on which
patients to treat should be based on prognostic factors
and the risk of progression. Although estimation of the
prognosis has mainly been based on clinical characteris-
tics, pathological features have also been reported as risk
factors for progression [1,2]. Several histologic* Correspondence: zhihong-liu@hotmail.com; agnes.fogo@Vanderbilt.Edu
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reproduction in any medium, provided the orclassification systems have been devised for predicting
progression of IgAN [3-7]. However, none has become
widely used [8], partly because the reproducibility of
histological variables were not tested in those
classifications.
The new Oxford classification of IgAN, based on 265
patients collected from eight countries on four conti-
nents, identified four definitive histological features,
with high reproducibility and low collinearity, for the
prediction of renal prognosis of IgAN: mesangial
hypercellularity (M), endocapillary proliferation (E), seg-
mental sclerosis or adhesion (S), and tubular atrophy/
interstitial fibrosis (T) [8,9]. However, the development
of the Oxford classification involved patients with an age
range encompassing pediatric and adult patients. SeveralThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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shown that the histological features of IgAN in children
and adults are remarkably different. Compared with
adults, children with IgAN showed significantly more
mesangial and endocapillary hypercellularity, and less
chronic tubulointerstitial and vascular damage [10-14].
Hence, whether the classification system has the similar
predictive power for children with IgAN in different
populations needs to be validated further.
Recently, several validation studies of the Oxford clas-
sification have been published [15-20], however, most of
these studies focused on adult patients with IgAN. A
study performed by Edström et. al [17] found that the
presence of S was not associated with the long-term
renal outcome in a cohort of pediatric IgAN patients
from Sweden. Shima et. al [19] analyzed 161 consecutive
children with IgAN from Japan and found that M, T,
and crescents (>30%) were significant univariate ana-
lyses. We herein report a multicenter validation study of
the Oxford classification, using similar inclusion criteria
and statistical analysis, in a cohort of children with IgAN
from China.
Methods
Inclusion criteria and clinical data set
Cases were biopsy-proven IgAN with age <18 years old,
and an initial eGFR ≥30 ml/min per 1.73m2, and initial
proteinuria ≥0.5g per 24 h, and total number of glom-
eruli ≥10 for analysis. Cases that were followed up ≥12
months, and those that had progressed to ESRD, regard-
less of the duration of follow-up, were included. Cases
with secondary causes of mesangial IgA deposits such as
Henoch–Schönlein purpura or those with comorbid
conditions such as diabetes mellitus, were excluded.
Demographic data included gender, ethnicity, date of
birth, date of initial presenting clinical features, and age
at biopsy. Clinical parameters collected within one
month of date of biopsy and during follow-up included
systolic and diastolic blood pressure, weight, height,
serum creatinine, albumin, cholesterol, triglyceride, and
24h urine protein or urine protein:creatinine ratio, count
of urine red blood cells, and macroscopic hematuria.
Treatment modalities were recorded including immuno-
suppressive agents, statins, tonsillectomy, and a number
of antihypertensive medications.
Definitions
Pathology definitions used were the same as in the ori-
ginal Oxford Classification [9]. eGFR was estimated
using the Schwartz formula; in patients aged >16 years
at the time of biopsy, only the MDRD equation was
used. ESRD was defined as eGFR < 15 ml/min per
1.73m2. A combined event was defined as ESRD or 50%
reduction in initial eGFR. MAP was defined as diastolicpressure plus 1/3 pulse pressure. For each patient, an
average MAP and proteinuria were determined for each
year of observation. Time-average MAP and proteinuria
represent the average of these annual values. Immuno-
suppressive treatment is reported as type and the dur-
ation of therapy. RAS blockade included any exposure to
either angiotensin converting enzyme inhibitor or angio-
tensin receptor blocker, or both.
Histological scoring
The exact biopsy tissue sections to be scored were marked
on the PAS slides. The scoring was done by two patholo-
gists (CH Z and SS L). The scoring sheet was based on the
Oxford classification of IgAN, and eight pathological vari-
ables, namely mesangial hypercellularity (M), endocapil-
lary proliferation (E), segmental sclerosis or adhesion (S),
crescents (C), glomerulus necrosis (N), tubular atrophy/
interstitial fibrosis (T), artery score, and malignant vascu-
lar changes were assessed. Capillary necrosis was scored
from all the slides of each case, including H&E, PAS,
PASM and Masson trichrome staining, so that this very
segmental lesion would be more likely to be identified.
Statistical analysis
Normally distributed variables were expressed as mean ±
S.D. and differences among groups were analyzed by Stu-
dent t-test or one-way ANOVA. Qualitative data were
described as percentages and analyzed using Chi-square
(χ2) test. Non-parametric variables were expressed as
median, and compared using either Mann–Whitney or
Kruskal–Wallis test.
The renal survival, estimated by a 50% reduction in
renal function or ESRD (the combined event) was used
as the primary outcome. Renal survival curves related to
pathological variables were calculated using the Kaplan–
Meier method, and comparisons were made with a
log-rank test. Cox regression was used to determine
predictors of renal outcome. The P-value reported was
two-sided and a value of less than 0.05 was considered sta-
tistically significant. CIs included 95% of predicted values.
All analyses were performed using R (Version 2.131).
The protocol followed in the present study was
approved by the Jinling Hospital Ethics Committee on
Human Experimentation(NO. 2010-NLY-024). Due to
the retrospective nature of the study, written informed
consent for participation in the study was waived .
Results
Clinical and pathological characteristics
A total of 218 pediatric patients were recruited from 7
different renal centers in China. Clinical features at bi-
opsy and during follow-up are shown in Table 1. At the
time of renal biopsy, the median age was 14 years,
with male (65%) predominance. Median proteinuria was
Table 1 Clinical characteristics at the time of biopsy and







At time of biopsy n = 218 n = 59 n = 161
Age (years) 14 (2–17.9) 13 (4–17.9) 11.7(3.6-19.4)
Female 35% 25% 37%
Hypertensive before biopsy 6.5% NA NA
MAP (mm Hg) 88 ± 11 84 ± 10 79 ± 11
eGFR (ml/min per 1.73 m2) 134 ± 42 120 ± 43 103 ± 30







56(12–182) 62 (20–268) 54 (12–170)
50% decline in eGFR
or ESRD
12.4% NA NA
MAP (mm Hg) 86 ± 10 86 ± 8 NA
Proteinuria (g/day) 0.6 (0.1-4.9) 0.9 (0.1–7.0) NA
Immunosuppression 56% 48% 16%
Prednisone 51% 48% 16%
Others 28.6% 17% 11%
Treated with RASB 61.5% 56% NA
Abbreviations: RASB, renin-angiotensin system blockade; eGFR, estimated
glomerular filtration rate; MAP, mean arterial pressure; ESRD, end stage renal
disease; NA, not available.
Values are expressed as mean ± s.d. or median (range). Calculation of MAP,
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Figure 1 Distribution of pathological features. Percentage of patients w
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24 children (12.4%) developed ESRD or 50% decline in
renal function. In general, the clinical characteristics in this
cohort were very similar to the pediatric patients in the ori-
ginal Oxford cohort. Compared with 161 children from
Japan, reported by Shima et al. [19], children in this cohort
and the original Oxford cohort had more severe proteinuria
at biopsy, and were treated with more RASB and immuno-
suppressive therapy during follow-up. Compared with 1026
adults in another multi-center validation cohort from
China [21], children in this cohort were also more likely to
have a history of macroscopic hematuria, to have higher
initial eGFR, and to receive more immunosuppressive ther-
apy but less antihypertensive therapy.
There were a median of 21 glomeruli per biopsy
(interquartile range 16–29). Distribution of several
pathology findings is shown in Figure 1. There were
98 patients (45%) with mesangial proliferation (M1), 51
patients (23%) with endocapillary proliferation (E1),
136 patients (62%) with segmental sclerosis/adhesion
lesion (S1), 13 patients (6%) with moderate tubuloin-
terstitial fibrosis (T1, 26-50% of cortex scarred), and
only 2 patients (1%) with severe tubulointerstitial fibrosis
(T2, >50% of cortex scarred). As T2 was seen in only two
cases in the current study, we merged T1 and T2 to-
gether in the following analyses. Crescents were seen in
95 cases (44%), however, the median ratio of glomeruli
with crescents was 9%, and only one patients showed
crescents involving greater than 50% of glomeruli. Capil-
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Table 2 Relations between clinical and histological
variables at time of biopsy
MAP eGFR Proteinuria
Mesangial hypercellularity score (M)
≤0.5 87 ± 11 133 ± 43 1.2 (0.81-2.2)
>0.5 90 ± 11 135 ± 40 1.9 (1.1-2.9)
P-value 0.03 0.8 0.002
Endocapillary proliferation (E)
Absent 87 ± 11 135 ± 42 1.3 (0.86-2.3)
Present 90 ± 12 130 ± 43 2.1 (1.1-3.0)
P-value 0.7 0.4 0.003
Segmental glomerulosclerosis (S-alone)
Absent 85 ± 10 135 ± 43 1.2 (0.78-2.2)
Present 92 ± 11 132 ± 41 1.7 (1.1-3.0)
P-value <0.001 0.7 <0.001
Segmental glomerulosclerosis or adhesion (S)
Absent 86 ± 10 138 ± 41 1.2 (0.79-2.3)
Present 90 ± 11 131 ± 42 1.6 (1.0-2.7)
P-value <0.001 0.3 0.01
Tubular atrophy / interstitial fibrosis (T)
T0 87 ± 11 136 ± 41 1.4 (0.89-2.5)
T1 or T2 96 ± 11 97 ± 44 2.4 (1.4-3.2)
P-value 0.009 0.004 0.03
Crescent( C)
Absent 87 ± 11 137 ± 42 1.2 (0.8-2.2)
Present 90 ± 11 129 ± 42 1.8 (1.1-3.2)
P-value 0.09 0.2 <0.001
Glomerulus necrosis (N)
Absent 87 ± 11 135 ± 42 1.4 (0.9-2.5)
Present 90 ± 12 125 ± 42 1.6 (0.9-2.9)
P-value 0.4 0.2 0.3
Abbreviations:eGFR, estimated glomerular filtration rate; MAP, mean arterial
pressure.
Values are expressed as mean ± s.d. or median (interquartile range).
Calculation of MAP, eGFR, and proteinuria is detailed in the text.







Mesangial hypercellularity score (M)
≤0.5 64 0.04 50 0.07
>0.5 78 64
Endocapillary proliferation (E)
Absent 69 0.6 54 0.4
Present 75 63
Segmental glomerulosclerosis (S-alone)
Absent 59 <0.001 53 0.5
Present 83 59
Segmental glomerulosclerosis or adhesion (S)
Absent 57 0.001 59 0.5
Present 79 54
Tubular atrophy / interstitial fibrosis (T)
Absent or Mild
(0%-25%)
68 0.03 57% 0.8
Moderate (>25%) 100 50%
Crescent (C)
Absent 62 0.002 47 0.004
Present 82 68
Glomerulus necrosis (N)
Absent 69 0.6 55 0.7
Present 76 61
Abbreviations: RASB, renin angiotensin system blockade.
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The clinicopathological correlations at the time of bi-
opsy are shown in Table 2. The M, E, S, T scores, and
crescents were strongly associated with proteinuria at bi-
opsy, and the M, S, and T scores were strongly asso-
ciated with MAP at biopsy. None of the lesions were
significantly associated with eGFR at the time of biopsy
except for tubular atrophy/interstitial fibrosis. Children
with T1 or T2 had a significantly lower eGFR compared
with those without (P =0.004). The E lesion and capillary
necrosis were not correlated with any of the clinical
features.Interaction of pathological features with therapy
The use of two major treatments, RAS blockade and im-
munosuppression, was assessed in relation to the
selected pathological lesions (Table 3). Compared with
adults in another multi-center validation cohort from
China [21] and Oxford study, children have received
more immunosuppressive treatment, but fewer RAS
blockade. Children with M, S, T, or C received subse-
quent RAS blockade more often than those without
those lesions. Those with crescent were more likely to
receive immunosuppressive treatment than those with-
out crescents. However, children with E were likely to
have an equal chance to receive immunosuppressive
treatment (P = 0.4) to those without E, as well as RAS
blockade treatment (P = 0.6). There were also no signifi-
cant association between the extent of E (% glomeruli
with these lesions) and immunosuppression during fol-
low up in this cohort.
Correlations between pathological lesions and outcome
Figure 2 shows the differences in renal survival from the
combined event for presence and absence of the histo-
logical findings. The Kaplan–Meier analyses showed
Figure 2 Renal survival according to pathological variables. M mesangial hypercellularity score, E endocapillary hypercellularity, S segmental
glomerulosclerosis or adhesion, T tubular atrophy/interstitial fibrosis, C crescents, N glomerulus necrosis.
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renal outcome, while lesion M, C, E and necrosis were
not.
The correlations between pathological lesions and
renal outcome were also analyzed in a COX regression
model (Table 4). The univariate COX regression model
showed that lesions S (HR 9.2, 95%CI 1.2-68.6, P = 0.03)
and T (HR 4.3, 95%CI 1.8-1.5, P = 0.001) were each sig-
nificantly associated with renal outcome, while the lesion
of M (HR 2.1, 95%CI 0.84-5.1, P = 0.1), E (HR 0.6, 95%CI
0.2-2.3, P = 0.5), C (HR 1.8, 95%CI 0.77-4.1, P = 0.2), and
necrosis (HR 0.6, 95%CI 0.14-1.7, P = 0.3) were not. In
the multivariate COX regression model, when adjusted
for initial clinical data set (eGFR, MAP, and proteinuria),
none of these pathologic lesions were shown to be inde-
pendent risk factors of unfavorable renal outcome except
for T (HR 2.9, 95%CI 1.0-7.9, P = 0.04).
The lesion S was defined as segmental glomerulo-
sclerosis or adhesion in the original Oxford study. We
have found that the segmental glomerulosclerosis alone
(S-alone, not involving the adhesion lesions) is a more
valuable pathological lesion than the defined as segmen-
tal sclerosis or adhesion lesion in 1026 adult patients
from China [21]. In this study, we also evaluated the pre-
dictive value of S-alone, instead of S with or without ad-
hesion. In univariate Cox regression analysis, children
with S-alone had a 3.8-fold higher risk of renal failure
than those without (95%CI: 1.3-11.1, P = 0.02). However,when adjusting the two pathology variables (lesions M
and T) and the initial clinical data set (eGFR, MAP, and
proteinuria), these association was not statistically
significant in the multivariate Cox regression analysis
(OR 2.2, 95%CI , P = 0.2).
Discussion
The Oxford classification of IgAN provides a histopatho-
logical grading system for prediction of renal prognosis
of IgAN independent of the clinical features [8,9]. How-
ever, the classification must be validated in the different
cohorts of patients. This study was designed, using simi-
lar methods as in the Oxford study, to assess the validity
of the new Oxford classification of IgAN in a multi-
center cohort of pediatric patients from China. The clin-
ical characteristics in our cohort were very similar to the
pediatric patients in original Oxford cohort (Table 1).
Our study shows that tubular interstitial fibrosis was the
only pathological feature independently associated with
renal outcomes in Chinese children with IgAN.
It is remarkable to notice that lesion M, E, C and N,
which were all thought to be active glomerular lesions in
patient with IgAN, were not independently associated
with renal outcome in our study. The similar results
were also showed in another validation study in 1026
Chinese adult patients [21]. Moreover, the prognostic
values of M, E and C were also controversial in different
validation studies [8,15-18,20,22-26]. The lesion E and C




P-value HR (95% CI)
Multivariateb
P-value
Mesangial hypercellularity score (M)
≤0.5 1.0 0.1 1.0 0.6
>0.5 2.1 (0.84-5.1) 1.3 (0.49-3.4)
Endocapillary proliferation (E)
Absent 1.0 0.5 1.0 0.2
Present 0.67 (0.2-2.3) 0.44 (0.12-1.5)
Segmental glomerulosclerosis or adhesion (S)
Absent 1.0 0.03 1.0 0.1
Present 9.2 (1.2-68.6) 5.2 (0.6-43)
Tubular atrophy / interstitial fibrosis (T)
T0 1.0 0.01 1.0 0.04
T1 or T2 4.3 (1.8-10.5) 2.9 (1.0-7.9)
Crescent (C)
Absent 1.0 0.2 NS
Present 1.8 (0.8-4.1)
Abbreviations: CI, confidence interval; OR, odds ratio; HR, hazard ratio. NS, not
significant.
bMultivariate Cox regression model: multivariate with four pathological
features (M,E,S,T) + initial eGFR, MAP and proteinuria.
Le et al. BMC Nephrology 2012, 13:158 Page 6 of 8
http://www.biomedcentral.com/1471-2369/13/158were also not statistically associated with renal outcome
in the original Oxford cohorts [8]. The prognostic value
of necrosis was not evaluated in the original Oxford
study, as only six cases (2.3%) had this lesion in that co-
hort of patients. Compared with patients in the Oxford
study, there were significantly more patients with necro-
sis (16%) in this study, however, an association between
necrosis and renal outcome was not established, and
similar results were also found in two other studies
[24,27]. Taken together, those results indicate that there
are only weak associations between present of these
acute lesions (M, E, C, N) and renal outcome. Several
possible explanations may account for these results.
Firstly, those acute glomerular lesions only reflect the
disease activity at the time of renal biopsy, and all of
them are reversible after immunosuppressive treatment
[28]. Secondly, the ration of glomeruli with these lesions
is very important in patients with IgAN, as most of the
patients have only small numbers of crescents in our
study and similar finding were also showed in other
studies [8,17,21]. Shima et. al [19] found that only those
patients with C > 30% or E > 30% were associated with
an unfavorable renal outcome in children with IgAN, in-
dicating that the optimal cutoff ratios of these acute
lesions for predicting a worse outcome should be deter-
mined in IgAN in the future. Thirdly, the inconsistent
results among those validation studies may due to differ-
ent inclusion criteria, as shown by Katafuchi et al.[29] and Shima et al. [19]. Finally, the lack of predictive
value of this lesion may reflect inadequate statistical
power, as only a small subset of patients developed
ESRD or 50% decline in GFR during the follow-up in
most validation studies, including the current study.
Recently, two studies about validation of the Oxford
classification for pediatric IgA nephropathy were pub-
lished from Japan and Sweden respectively. The most
obvious difference between our study and the two previ-
ous studies is lesion S. Both Shima et. al [19] Edström
et. al [17] found that present of lesion didn’t indicate a
poor prognosis in IgAN. In the present study, present
of lesion S were showed to be significantly associated
with renal outcome in univariate COX analysis, but it
failed to attain independent significance in multivariate
model. A similar predictive value was shown between S
and S-alone in this cohort. This may due to the differ-
ent health screening practice and inclusion criteria,
various treatments during follow-up, and especially the
poor reproducibility (ICC) of lesion S. Children in this
study have more severe proteinuria at biopsy, and
received more RASB and immunosuppressive therapy
during follow-up than children from Japan [19]. Given
that the ICC of adhesion was poor (0.2) in the original
Oxford study, the frequency distribution of S was also
remarkably different among the validation studies.
Taken together, these findings indicate that lesion S
seems to had a weak influence on renal survival.
One of the most exciting findings in the new Oxford
IgAN classification, is the question of whether this clas-
sification can predict optimal treatment for patients with
IgAN. The original Oxford study showed that, in
patients who received no immunosuppression, the rate
of renal function decline in those with E was faster than
those without, while there was no such difference in
patients treated with immunosuppression. Hence, the le-
sion E was finally involved in the Oxford classification,
and this provided indirect evidence that lesion E is
assumed responsive to immunosuppressive therapy. The
similar indirect evidence was also shown in a validation
study from four centers in North America [16]. How-
ever, in the current cohort of patients, we do not con-
firm these findings. Whether lesion C, E, and N can
predict optimal treatment for patients with IgAN
remains unclear, and prospective clinicopathological
studies are needed to investigate this possibility.
IgAN is defined as dominant or codominant staining
with IgA in glomeruli by immunofluorescence or immu-
noperoxidase [9]. It is important to note that it may in
fact simply define a group of diseases sharing identical
histopathologic sequelae [30]. If that is the case, a great
limitation of this histopathological classification should
be recognized, for an ideal classification system should
be based on pathogenic mechanisms and should thus
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cation of IgAN should also be improved based on the
biomarker of pathogenic mechanisms in the future.
Conclusions
Our study indicates tubular atrophy/interstitial fibrosis
was the most powerful lesion for prediction of renal
prognosis of IgAN independent of clinical features, while
segmental glomerulosclerosis had a weak influence on
renal survival. Mesangial hypercellularity, endocapillary
hypercellularity, crescent and capillary necrosis were not
associated with the renal outcome. Whether the Oxford
classification can predict an optimal treatment for chil-
dren of varying ethnicity with IgAN remains unclear.
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